Cybrexa, Inc.

Cybrexa, Inc.

Cybrexa, Inc.

Date Founded



5 Science Park,395 Winchester Avenue,New Haven, CT 06511

Type of Company


Employees (Worldwide)

1 - 10


Holding Companies

Company Description

Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT.

Executives & Employees

President, Chief Executive Officer & Director

Chief Scientific Officer

Chief Medical Advisor


Vice President, Marketing

Scientific Advisor

Board of Directors

President, Chief Executive Officer & Founder at CiDRA Corporate Services, Inc.

Executive Chairman at Aziyo Biologics, Inc.

President & Chief Executive Officer at Arvinas, Inc.

President, Chief Executive Officer & Director at Cybrexa, Inc.

Paths to Cybrexa, Inc.
Potential Connections via
Relationship Science
Cybrexa, Inc.
Details Hidden

Elm Street Venture Advisors, Inc. invests in companies located in the US. The fund targets companies operating in the fields of life Sciences, including therapeutics, medical devices, diagnostics, research tools and services, materials, healthcare, and healthcare services Clean technology, with an emphasis on green chemistry; and Information technology including mobile and social web. It provides financing for seed and early stage capital requirements with an initial investment size of $0.1 million to $2.5 million. It also makes follow-on investments.

Details Hidden

HighCape Partners Management is an active manager which invests in companies located in the US. The firm follows of commercial-stage life sciences companies. It provides financing for growth stage capital requirements.

Details Hidden

Connecticut Innovations invests in companies located in the US, primarily in Connecticut. The firm targets companies operating in the fields of bioscience, biomedical engineering, medical care, medical devices, pharmaceuticals, genomics, molecular science and biomedical engineering. The firm provides financing for seed and early stage ranging up to $500,000.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cybrexa, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cybrexa, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Cybrexa, Inc..